目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 23)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SEGMENTATION
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH APPROACH
FIGURE 1 CONTRAST ENHANCED ULTRASOUND MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 MARKET SIZE ESTIMATION FOR CONTRAST ENHANCED ULTRASOUND INDUSTRY: APPROACH 1 (COMPANY REVENUE ESTIMATION)
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF GE HEALTHCARE
2.2.1.2 Approach 2: Customer-based market estimation
FIGURE 7 BOTTOM-UP APPROACH FOR MARKET SIZE ESTIMATION
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 DATA TRIANGULATION APPROACH
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET ASSUMPTIONS
2.5 RISK ASSESSMENT
2.5.1 RISK ASSESSMENT ANALYSIS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 41)
FIGURE 10 CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 CONTRAST ENHANCED ULTRASOUND INDUSTRY, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 45)
4.1 CONTRAST ENHANCED ULTRASOUND MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
4.2 EUROPE: MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 15 CONTRAST AGENTS SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
4.3 NORTH AMERICA: MARKET, BY APPLICATION, 2023 VS. 2028
FIGURE 16 THERAPEUTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 ASIA PACIFIC: MARKET, BY END USER
FIGURE 17 HOSPITALS AND SURGICAL CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 50)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 CONTRAST ENHANCED ULTRASOUND MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic diseases
5.2.1.2 Rising technological advancements in contrast-enhanced ultrasound systems
5.2.1.3 Increasing initiatives for commercialization of diagnostic imaging equipment
5.2.2 RESTRAINTS
5.2.2.1 Risks associated with contrast agents
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Increasing establishment of hospitals and diagnostic imaging centers
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled sonographers
5.2.4.2 Presence of alternative techniques
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 1 CONTRAST ENHANCED ULTRASOUND INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TRADE ANALYSIS
TABLE 2 IMPORT DATA FOR ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2022 (USD THOUSAND)
TABLE 3 EXPORT DATA FOR ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2022 (USD THOUSAND)
TABLE 4 IMPORT DATA FOR CONTRAST AGENTS, BY COUNTRY, 2018-2022 (USD THOUSAND)
TABLE 5 EXPORT DATA FOR CONTRAST AGENTS, BY COUNTRY, 2018-2022 (USD THOUSAND)
5.5 PATENT ANALYSIS
FIGURE 20 TOP 10 PATENT APPLICANTS (JANUARY 2012-DECEMBER 2022)
5.6 ECOSYSTEM COVERAGE OF PARENT MARKET
5.7 VALUE CHAIN ANALYSIS
5.7.1 RESEARCH & DEVELOPMENT
5.7.2 MANUFACTURING & ASSEMBLY
5.7.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
FIGURE 21 VALUE CHAIN ANALYSIS
5.8 SUPPLY CHAIN ANALYSIS
5.8.1 PROMINENT COMPANIES
5.8.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.8.3 END USERS
FIGURE 22 SUPPLY CHAIN ANALYSIS
5.9 PRICING TREND ANALYSIS
TABLE 6 AVERAGE SELLING PRICE FOR MAJOR CONTRAST-ENHANCED ULTRASOUND EQUIPMENT
5.10 TECHNOLOGY ANALYSIS
5.11 REGULATORY LANDSCAPE
5.11.1 NORTH AMERICA
5.11.1.1 US
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.11.1.2 Canada
TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.11.2 EUROPE
5.11.3 ASIA PACIFIC
5.11.3.1 Japan
TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.11.3.2 China
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.11.3.3 India
5.12 REIMBURSEMENT SCENARIO
TABLE 12 MEDICAL REIMBURSEMENT CODES FOR CONTRAST-ENHANCED ULTRASOUND PROCEDURES
5.13 CASE STUDIES
5.13.1 TECHNICAL CHALLENGES WITH ULTRASOUND SYSTEMS
TABLE 13 CASE STUDY 1: IMPROVED SENSITIVITY AND BETTER VISIBILITY OF BLOOD FLOW
5.14 KEY CONFERENCES AND EVENTS
TABLE 14 MARKET: LIST OF MAJOR CONFERENCES AND EVENTS (2023-2024)

6 CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE (Page No. - 72)
6.1 INTRODUCTION
TABLE 15 CONTRAST ENHANCED ULTRASOUND INDUSTRY, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
6.2 EQUIPMENT
6.2.1 INNOVATIVE PRODUCT LAUNCHES WITH IMPROVED DIAGNOSIS AND REAL-TIME MONITORING ABILITIES TO DRIVE MARKET
TABLE 16 MARKET FOR EQUIPMENT, BY REGION, 2021-2028 (USD MILLION)
6.3 CONTRAST AGENTS
TABLE 17 MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 18 MARKET FOR CONTRAST AGENTS, BY REGION, 2021-2028 (USD MILLION)
6.3.1 MOLECULE-TARGETED MICROBUBBLES
6.3.1.1 Rising use in targeted therapies to drive market
TABLE 19 MARKET FOR MOLECULE-TARGETED MICROBUBBLES, BY REGION, 2021-2028 (USD MILLION)
6.3.2 NANOPARTICLE MICROBUBBLES
6.3.2.1 Utilization in thermal therapies to fuel market
TABLE 20 MARKET FOR NANOPARTICLE MICROBUBBLES, BY REGION, 2021-2028 (USD MILLION)
6.4 SOFTWARE AND SERVICES
6.4.1 RISING UTILIZATION OF SOFTWARE FOR OPTIMAL IMAGE VISUALIZATION TO DRIVE MARKET
TABLE 21 MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 CONTRAST ENHANCED ULTRASOUND MARKET, BY APPLICATION (Page No. - 79)
7.1 INTRODUCTION
TABLE 22 CONTRAST ENHANCED ULTRASOUND INDUSTRY, BY APPLICATION, 2021-2028 (USD MILLION)
7.2 DIAGNOSTIC APPLICATIONS
TABLE 23 MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
7.2.1 CARDIOLOGY
7.2.1.1 Increasing incidence of CVD to drive market
TABLE 24 MARKET FOR DIAGNOSTIC CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.2.2 HEPATIC
7.2.2.1 Utilization of CEUS technology in characterization of focal liver lesions to drive market
TABLE 25 MARKET FOR DIAGNOSTIC HEPATIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.2.3 NEPHROLOGY
7.2.3.1 Ability to identify renal complications to propel market
TABLE 26 MARKET FOR DIAGNOSTIC NEPHROLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.2.4 OTHER DIAGNOSTIC APPLICATIONS
TABLE 27 MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.3 THERAPEUTIC APPLICATIONS
TABLE 28 MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
7.3.1 CARDIOLOGY
7.3.1.1 Growing applications in targeted drug delivery to propel market
TABLE 29 MARKET FOR THERAPEUTIC CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.3.2 VASCULAR
7.3.2.1 Growing use of contrast agents in blood flow dynamics to fuel market
TABLE 30 MARKET FOR THERAPEUTIC VASCULAR APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.3.3 ONCOLOGY
7.3.3.1 Rising utilization in targeted therapy to drive market
TABLE 31 MARKET FOR THERAPEUTIC ONCOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
7.3.4 OTHER THERAPEUTIC APPLICATIONS
TABLE 32 MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

8 CONTRAST ENHANCED ULTRASOUND MARKET, BY END USER (Page No. - 88)
8.1 INTRODUCTION
TABLE 33 CONTRAST ENHANCED ULTRASOUND INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
8.2 HOSPITALS AND SURGICAL CENTERS
8.2.1 RISING NUMBER OF CEUS-BASED MEDICAL PROCEDURES TO DRIVE MARKET
TABLE 34 MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)
8.3 DIAGNOSTIC IMAGING CENTERS
8.3.1 RISING ESTABLISHMENT OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
TABLE 35 MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021-2028 (USD MILLION)
8.4 AMBULATORY SURGERY CENTERS
8.4.1 RISING VOLUME OF EMERGENCY SURGERIES TO PROPEL MARKET
TABLE 36 MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2028 (USD MILLION)
8.5 OTHER END USERS
TABLE 37 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

9 CONTRAST ENHANCED ULTRASOUND MARKET, BY REGION (Page No. - 93)
9.1 INTRODUCTION
TABLE 38 CONTRAST ENHANCED ULTRASOUND INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: MARKET SNAPSHOT
9.2.1 NORTH AMERICA: RECESSION IMPACT
TABLE 39 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 41 NORTH AMERICA: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 44 NORTH AMERICA: MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
9.2.2 US
9.2.2.1 High adoption rate of innovative medical technologies to drive market
TABLE 46 US: CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 47 US: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.2.3 CANADA
9.2.3.1 Increasing incidence of heart & kidney diseases to drive market
TABLE 48 CANADA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 49 CANADA: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.3 EUROPE
9.3.1 EUROPE: RECESSION IMPACT
TABLE 50 EUROPE: CONTRAST ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 51 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 52 EUROPE: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 54 EUROPE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 55 EUROPE: MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 56 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 High healthcare expenditure to propel market
TABLE 57 GERMANY: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 58 GERMANY: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising target patient population and government-funded investments for advanced medical equipment to fuel uptake
TABLE 59 FRANCE: CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 60 FRANCE: CONTRAST ENHANCED ULTRASOUND INDUSTRY FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.3.4 UK
9.3.4.1 Increasing investments in diagnostic imaging to drive market
TABLE 61 UK: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 62 UK: CONTRAST-ENHANCED ULTRASOUND FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.3.5 REST OF EUROPE
TABLE 63 REST OF EUROPE: CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 64 REST OF EUROPE: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: MARKET SNAPSHOT
9.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 65 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 66 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 67 ASIA PACIFIC: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 ASIA PACIFIC: MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 71 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Presence of universal healthcare reimbursement system to support market growth
TABLE 72 JAPAN: CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 73 JAPAN: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.4.3 CHINA
9.4.3.1 Rising government initiatives for improvements in healthcare infrastructure to drive market
TABLE 74 CHINA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 75 CHINA: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.4.4 INDIA
9.4.4.1 Growing public-private investments in novel medical technologies to drive market
TABLE 76 INDIA: CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 77 INDIA: CONTRAST ENHANCED ULTRASOUND INDUSTRY FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 78 REST OF ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 79 REST OF ASIA PACIFIC: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
9.5 REST OF THE WORLD
9.5.1 REST OF THE WORLD: RECESSION IMPACT
TABLE 80 REST OF THE WORLD: CONTRAST ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 81 REST OF THE WORLD: MARKET FOR CONTRAST AGENTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 82 REST OF THE WORLD: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 83 REST OF THE WORLD: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 84 REST OF THE WORLD: MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 REST OF THE WORLD: MARKET, BY END USER, 2021-2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 122)
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 25 CONTRAST ENHANCED ULTRASOUND MARKET: KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS
FIGURE 26 CONTRAST ENHANCED ULTRASOUND INDUSTRY: REVENUE SHARE ANALYSIS OF LEADING PLAYERS (2022)
10.4 MARKET SHARE ANALYSIS
FIGURE 27 MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022)
TABLE 86 MARKET: INTENSITY OF COMPETITIVE RIVALRY
10.5 COMPANY EVALUATION MATRIX (2022)
10.5.1 STARS
10.5.2 PERVASIVE PLAYERS
10.5.3 EMERGING LEADERS
10.5.4 PARTICIPANTS
FIGURE 28 MARKET: COMPANY EVALUATION MATRIX (2022)
10.6 COMPETITIVE BENCHMARKING
TABLE 87 MARKET: PRODUCT & REGIONAL FOOTPRINT ANALYSIS
10.7 COMPETITIVE SCENARIO AND TRENDS
10.7.1 PRODUCT LAUNCHES
TABLE 88 MARKET: PRODUCT LAUNCHES (JANUARY 2020-JULY 2023)
10.7.2 DEALS
TABLE 89 MARKET: DEALS (JANUARY 2020-JULY 2023)
10.7.3 OTHER DEVELOPMENTS
TABLE 90 MARKET: OTHER DEVELOPMENTS (JANUARY 2020−JULY 2023)

11 COMPANY PROFILES (Page No. - 131)
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 GE HEALTHCARE
TABLE 91 GE HEALTHCARE: COMPANY OVERVIEW
FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.2 LANTHEUS
TABLE 92 LANTHEUS: COMPANY OVERVIEW
FIGURE 30 LANTHEUS: COMPANY SNAPSHOT (2022)
11.1.3 BRACCO IMAGING S.P.A.
TABLE 93 BRACC0 IMAGING S.P.A.: COMPANY OVERVIEW
11.1.4 KONINKLIJKE PHILIPS N.V.
TABLE 94 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
FIGURE 31 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
11.1.5 SIEMENS HEALTHINEERS
TABLE 95 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
FIGURE 32 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022)
11.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
TABLE 96 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
FIGURE 33 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
11.1.7 CANON INC.
TABLE 97 CANON INC.: COMPANY OVERVIEW
FIGURE 34 CANON INC.: COMPANY SNAPSHOT (2022)
11.1.8 ESAOTE S.P.A
TABLE 98 ESAOTE S.P.A: COMPANY OVERVIEW
11.1.9 SAMSUNG ELECTRONICS CO., LTD.
TABLE 99 SAMSUNG ELECTRONICS CO., LTD.: COMPANY OVERVIEW
FIGURE 35 SAMSUNG ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
11.1.10 GUERBET
TABLE 100 GUERBET: COMPANY OVERVIEW
FIGURE 36 GUERBET: COMPANY SNAPSHOT (2022)
11.2 OTHER PLAYERS
11.2.1 NANOPET PHARMA GMBH
11.2.2 BAYER AG
11.2.3 REVVITY
11.2.4 SOLSTICE PHARMACEUTICALS B.V.
11.2.5 TRIVITRON HEALTHCARE
11.2.6 LERIVA
11.2.7 JB PHARMA
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 167)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS